Risk  ||| S:0 E:5 ||| NN
stratification  ||| S:5 E:20 ||| NN
for  ||| S:20 E:24 ||| IN
thromboembolism  ||| S:24 E:40 ||| NN
and  ||| S:40 E:44 ||| CC
antithrombotic  ||| S:44 E:59 ||| FW
prophylaxis  ||| S:59 E:71 ||| FW
in  ||| S:71 E:74 ||| FW
atrial  ||| S:74 E:81 ||| FW
fibrillation  ||| S:81 E:94 ||| FW
Atrial  ||| S:94 E:101 ||| FW
fibrillation  ||| S:101 E:114 ||| FW
( ||| S:114 E:115 ||| -LRB-
AF ||| S:115 E:117 ||| NNP
)  ||| S:117 E:119 ||| -RRB-
is  ||| S:119 E:122 ||| VBZ
associated  ||| S:122 E:133 ||| VBN
with  ||| S:133 E:138 ||| IN
a  ||| S:138 E:140 ||| DT
significantly  ||| S:140 E:154 ||| RB
high  ||| S:154 E:159 ||| JJ
risk  ||| S:159 E:164 ||| NN
of  ||| S:164 E:167 ||| IN
stroke  ||| S:167 E:174 ||| NN
and  ||| S:174 E:178 ||| CC
systemic  ||| S:178 E:187 ||| JJ
embolism  ||| S:187 E:196 ||| NNS
( ||| S:196 E:197 ||| -LRB-
4.5 ||| S:197 E:200 ||| CD
% ||| S:200 E:201 ||| NN
/ ||| S:201 E:202 ||| CD
year ||| S:202 E:206 ||| NN
) ||| S:206 E:207 ||| -RRB-
.  ||| S:207 E:209 ||| .
Oral  ||| S:209 E:214 ||| JJ
anticoagulant  ||| S:214 E:228 ||| JJ
therapy  ||| S:228 E:236 ||| NN
( ||| S:236 E:237 ||| -LRB-
OAT ||| S:237 E:240 ||| NNP
)  ||| S:240 E:242 ||| -RRB-
with  ||| S:242 E:247 ||| IN
warfarin  ||| S:247 E:256 ||| NNS
( ||| S:256 E:257 ||| -LRB-
INR  ||| S:257 E:261 ||| NNP
range  ||| S:261 E:267 ||| NN
2.0-3.0 ||| S:267 E:274 ||| CD
)  ||| S:274 E:276 ||| -RRB-
significantly  ||| S:276 E:290 ||| RB
reduces  ||| S:290 E:298 ||| VBZ
thromboembolic  ||| S:298 E:313 ||| JJ
risk ||| S:313 E:317 ||| NN
,  ||| S:317 E:319 ||| ,
whereas  ||| S:319 E:327 ||| IN
aspirin  ||| S:327 E:335 ||| NN
has  ||| S:335 E:339 ||| VBZ
poor  ||| S:339 E:344 ||| JJ
efficacy ||| S:344 E:352 ||| NN
.  ||| S:352 E:354 ||| .
In  ||| S:354 E:357 ||| IN
patients  ||| S:357 E:366 ||| NNS
with  ||| S:366 E:371 ||| IN
AF ||| S:371 E:373 ||| NNP
,  ||| S:373 E:375 ||| ,
several  ||| S:375 E:383 ||| JJ
scoring  ||| S:383 E:391 ||| JJ
systems ||| S:391 E:398 ||| NNS
,  ||| S:398 E:400 ||| ,
such  ||| S:400 E:405 ||| JJ
as  ||| S:405 E:408 ||| IN
the  ||| S:408 E:412 ||| DT
CHADS2  ||| S:412 E:419 ||| NNP
and  ||| S:419 E:423 ||| CC
CHA2DS2-VASc  ||| S:423 E:436 ||| CD
scores ||| S:436 E:442 ||| NNS
,  ||| S:442 E:444 ||| ,
are  ||| S:444 E:448 ||| VBP
currently  ||| S:448 E:458 ||| RB
used  ||| S:458 E:463 ||| VBN
to  ||| S:463 E:466 ||| TO
stratify  ||| S:466 E:475 ||| VB
thromboembolic  ||| S:475 E:490 ||| JJ
risk ||| S:490 E:494 ||| NN
.  ||| S:494 E:496 ||| .
The  ||| S:496 E:500 ||| DT
CHA2DS2-VASc  ||| S:500 E:513 ||| JJ
score  ||| S:513 E:519 ||| NN
stratifies  ||| S:519 E:530 ||| NN
patients  ||| S:530 E:539 ||| NNS
at  ||| S:539 E:542 ||| IN
intermediate-low  ||| S:542 E:559 ||| JJ
thromboembolic  ||| S:559 E:574 ||| JJ
risk  ||| S:574 E:579 ||| NN
more  ||| S:579 E:584 ||| RBR
accurately  ||| S:584 E:595 ||| RB
than  ||| S:595 E:600 ||| IN
the  ||| S:600 E:604 ||| DT
CHADS2  ||| S:604 E:611 ||| JJ
score ||| S:611 E:616 ||| NN
.  ||| S:616 E:618 ||| .
The  ||| S:618 E:622 ||| DT
most  ||| S:622 E:627 ||| RBS
recent  ||| S:627 E:634 ||| JJ
European  ||| S:634 E:643 ||| JJ
and  ||| S:643 E:647 ||| CC
US  ||| S:647 E:650 ||| NNP
guidelines  ||| S:650 E:661 ||| NNS
on  ||| S:661 E:664 ||| IN
AF  ||| S:664 E:667 ||| NNP
have  ||| S:667 E:672 ||| VBP
extended  ||| S:672 E:681 ||| VBN
the  ||| S:681 E:685 ||| DT
indications  ||| S:685 E:697 ||| NNS
for  ||| S:697 E:701 ||| IN
OAT ||| S:701 E:704 ||| NNP
,  ||| S:704 E:706 ||| ,
which  ||| S:706 E:712 ||| WDT
is  ||| S:712 E:715 ||| VBZ
recommended  ||| S:715 E:727 ||| VBN
not  ||| S:727 E:731 ||| RB
only  ||| S:731 E:736 ||| RB
for  ||| S:736 E:740 ||| IN
patients  ||| S:740 E:749 ||| NNS
at  ||| S:749 E:752 ||| IN
high  ||| S:752 E:757 ||| JJ
risk ||| S:757 E:761 ||| NN
,  ||| S:761 E:763 ||| ,
but  ||| S:763 E:767 ||| CC
also  ||| S:767 E:772 ||| RB
for  ||| S:772 E:776 ||| IN
those  ||| S:776 E:782 ||| DT
at  ||| S:782 E:785 ||| IN
intermediate  ||| S:785 E:798 ||| JJ
risk ||| S:798 E:802 ||| NN
,  ||| S:802 E:804 ||| ,
with  ||| S:804 E:809 ||| IN
CHADS2  ||| S:809 E:816 ||| CD
score  ||| S:816 E:822 ||| CD
â‰¥1 ||| S:822 E:824 ||| CD
.  ||| S:824 E:826 ||| .
However ||| S:826 E:833 ||| RB
,  ||| S:833 E:835 ||| ,
in  ||| S:835 E:838 ||| IN
clinical  ||| S:838 E:847 ||| JJ
practice  ||| S:847 E:856 ||| NN
underuse  ||| S:856 E:865 ||| NN
of  ||| S:865 E:868 ||| IN
OAT ||| S:868 E:871 ||| NNP
,  ||| S:871 E:873 ||| ,
suboptimal  ||| S:873 E:884 ||| JJ
quality  ||| S:884 E:892 ||| NN
of  ||| S:892 E:895 ||| IN
anticoagulation ||| S:895 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
and  ||| S:912 E:916 ||| CC
frequent  ||| S:916 E:925 ||| JJ
discontinuations  ||| S:925 E:942 ||| NN
of  ||| S:942 E:945 ||| IN
treatment  ||| S:945 E:955 ||| NN
are  ||| S:955 E:959 ||| VBP
observed ||| S:959 E:967 ||| VBN
.  ||| S:967 E:969 ||| .
Therefore ||| S:969 E:978 ||| RB
,  ||| S:978 E:980 ||| ,
there  ||| S:980 E:986 ||| EX
is  ||| S:986 E:989 ||| VBZ
a  ||| S:989 E:991 ||| DT
great  ||| S:991 E:997 ||| JJ
expectation  ||| S:997 E:1009 ||| NN
for  ||| S:1009 E:1013 ||| IN
the  ||| S:1013 E:1017 ||| DT
new  ||| S:1017 E:1021 ||| JJ
oral  ||| S:1021 E:1026 ||| JJ
anticoagulants ||| S:1026 E:1040 ||| NN
,  ||| S:1040 E:1042 ||| ,
in  ||| S:1042 E:1045 ||| IN
particular  ||| S:1045 E:1056 ||| JJ
the  ||| S:1056 E:1060 ||| DT
direct  ||| S:1060 E:1067 ||| JJ
thrombin  ||| S:1067 E:1076 ||| FW
inhibitor  ||| S:1076 E:1086 ||| FW
dabigatran  ||| S:1086 E:1097 ||| FW
etexilate  ||| S:1097 E:1107 ||| FW
and  ||| S:1107 E:1111 ||| CC
the  ||| S:1111 E:1115 ||| DT
factor  ||| S:1115 E:1122 ||| NN
Xa  ||| S:1122 E:1125 ||| FW
inhibitors  ||| S:1125 E:1136 ||| FW
rivaroxaban  ||| S:1136 E:1148 ||| FW
and  ||| S:1148 E:1152 ||| CC
apixaban ||| S:1152 E:1160 ||| NN
,  ||| S:1160 E:1162 ||| ,
which  ||| S:1162 E:1168 ||| WDT
are  ||| S:1168 E:1172 ||| VBP
at  ||| S:1172 E:1175 ||| IN
least  ||| S:1175 E:1181 ||| JJS
non-inferior  ||| S:1181 E:1194 ||| JJ
to  ||| S:1194 E:1197 ||| TO
warfarin  ||| S:1197 E:1206 ||| VB
and  ||| S:1206 E:1210 ||| CC
safer ||| S:1210 E:1215 ||| JJR
,  ||| S:1215 E:1217 ||| ,
and  ||| S:1217 E:1221 ||| CC
seem  ||| S:1221 E:1226 ||| VBP
to  ||| S:1226 E:1229 ||| TO
be  ||| S:1229 E:1232 ||| VB
a  ||| S:1232 E:1234 ||| DT
suitable  ||| S:1234 E:1243 ||| JJ
therapeutic  ||| S:1243 E:1255 ||| JJ
alternative  ||| S:1255 E:1267 ||| NN
to  ||| S:1267 E:1270 ||| TO
the  ||| S:1270 E:1274 ||| DT
old  ||| S:1274 E:1278 ||| JJ
warfarin ||| S:1278 E:1286 ||| NN
.  ||| S:1286 E:1288 ||| .
